

Equities



MALAYSIA

MRC MK	Outperform
Price (at 08:44, 30 Nov 2016 GMT)	RM1.31

Valuation - DCF (WACC 8.1%, beta 1.1, ERP 6.5)	RM %, RFR 4.5%	1.85
12-month target	RM	1.85
Upside/Downside	%	+41.2
12-month TSR	%	+43.1
Volatility Index		Medium
GICS sector	Capi	tal Goods
Market cap	RMm	2,809
Market cap	US\$m	629
30-day avg turnover	US\$m	0.5
Number shares on issue	m	2,144

Investment fundamentals

Year end 31 Dec		2015A	2016E	2017E	2018E
Revenue	m	1,696.7	1,751.9	1,946.4	2,132.6
EBITDA	m	242.3	343.3	398.0	455.9
EBITDA growth	%	-17.6	41.7	15.9	14.6
EBIT	m	178.2	276.6	322.2	367.9
EBIT growth	%	-26.2	55.2	16.5	14.2
Reported profit	m	330.4	118.7	138.4	179.2
Adjusted profit	m	0.8	74.3	138.4	179.2
EPS rep	sen	17.3	6.1	6.0	7.8
EPS rep growth	%	161.0	-65.0	-1.5	31.0
EPS adj	sen	0.0	3.8	6.0	7.8
EPS adj growth	%	-95.2	8,577.5	57.3	30.9
PER rep	Х	7.6	21.6	21.9	16.7
PER adj	Х	2,994.6	34.5	21.9	16.8
Total DPS	sen	2.5	2.5	2.5	2.5
Total DPS growth	%	0.0	0.0	0.0	0.0
Total div yield	%	1.9	1.9	1.9	1.9
ROA	%	2.5	4.0	4.5	4.8
ROE	%	0.0	3.0	5.0	6.2
EV/EBITDA	Х	22.3	15.1	14.0	12.3
Net debt/equity	%	124.2	78.1	82.5	81.0
P/BV	Х	1.4	1.2	1.3	1.2

MRC MK rel KLCI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.

Source: FactSet, Macquarie Research, November 2016 (all figures in MYR unless noted)

Analyst(s) Aiman Mohamad

+60 3 2059 8986 aiman.mohamad@macquarie.com

1 December 2016 Macquarie Capital Securities (Malaysia) Sdn. Bhd.

MRCB

Major earnings lift possible in 4Q16

Event

- MRCB reported its 3Q16 results on 30 November 2016.
- MRCB's cumulative 9M16 rep. PAT registered at RM79mn (-74% y/y); this is 67% of Macquarie's FY16E estimates and 72% of consensus FY16E forecasts. On the quarterly results, 3Q16 rep. PAT jumped 564% y/y to RM29mn due to the rise in revenue by 47% y/y to RM551mn. Earnings were weaker in 9M16 due to the RM279mn gain recorded from MRCB's asset disposal program in 9M15.

Impact

- Property division to lift earnings in 4Q16. MRCB's shareholders approved the resolution to dispose the Menara Shell at RM640mn, during an EGM, which took place today. MRCB expects the disposal to bring RM89mn gain for MRCB in FY16E. Menara Shell will be sold to MRCB's REIT arm MRCB-Quill REIT, paid in cash and REIT units. Recall that MRCB has also agreed to sell its land plot in the KLCC vicinity called The Grid to MRT Corp in a deal worth RM180mn. The land disposal is estimated to bring after-tax gain of RM38.1mn to MRCB. These disposals should lift MRCB's consolidated earnings in 4Q16.
- Property division exceeded MRCB's FY16E sales target. In light of the proposed sale of Menara Shell, MRCB's YTD property sales registered at RM1.17bn, exceeding its RM1bn FY16E sales target. Its unbilled sales stood at RM1.4bn and MRCB is planning to launch two more property projects in December 2016 Kalista in Bukit Rahman Putra and Sentral Suites, carrying a combined GDV of RM1.35bn. Based on the soft launches of these projects, Kalista and Sentral Suites have had 50% and 45% bookings, respectively.
- Construction division showed signs of life with margin expansion. EBIT margin for the construction division expanded to 4.8% in 3Q16 vs. 1.8% in 2Q16 as MRCB begins to recognize the value of its orderbook, which currently stands at RM5.2bn. YTD earnings for this division were weaker due to the loss recognition from the LRT2 project. Going forward we expect margins to expand further as MRCB moves on from the loss-making legacy projects inherited from the previous management.

Earnings and target price revision

No change.

Price catalyst

- 12-month price target: RM1.85 based on a Sum of Parts methodology.
- Catalyst: new order wins for MRCB's construction and engineering division

Action and recommendation

MRCB is our top pick in the Malaysian property sector, as we believe its transport-oriented development (TOD) projects will bode well with the completion of the upcoming mega infra projects in Malaysia, and hence will generate strong take-up rates. MRCB is also one of our top picks in the <u>ASEAN Emerging Leaders</u> – Macquarie's top picks in the ASEAN small mid cap (SMID) coverage. Maintain Outperform.

Analysis

Fig 1 Breakdown of 3Q16 results

RM 'mil			Quarterly				Cumulativ	е
	3Q16	3Q15	YoY (%)	2Q16	QoQ (%)	9M16	9M15	YoY (%)
Revenue	551	374	47.4%	389	41.6%	1,376	1,309	5.2%
EBIT	86	55	56.3%	107	-19.9%	255	466	-45.2%
Interest income	3	7	-59.3%	2	28.3%	7	29	-74.5%
Finance costs	-42	-44	5.6%	-44	5.5%	-133	-134	0.8%
Associates and JV	15	8	90.3%	9	70.7%	24	8	199.7%
Pre-tax income	62	25	143.2%	74	-16.5%	154	370	-58.3%
Net Profit*	29	4	564.3%	46	-35.4%	79	299	-73.5%
EPS (sen)*	1.5	0.3	496.0%	2.5	-39.9%	4.2	16.8	-74.8%
Segmental Analysis								
Revenue								
Property	354	89	296.3%	224	58.0%	731	567	28.9%
Construction	147	234	-37.2%	103	41.9%	479	595	-19.4%
Infrastructure	28	29	-2.1%	29	-3.0%	85	86	-1.1%
Facilities Management	15	18	-17.1%	19	-20.6%	52	55	-4.1%
Others	7	4	97.7%	13	-48.3%	28	5	439.9%
Total	551	374	47.4%	389	42%	1,376	1,309	5.2%
<u>EBIT</u>								
Property	70	8	838.8%	90	-22.1%	228	360	-36.6%
Construction	7	50	-85.9%	2	283.5%	10	79	-87.4%
Infrastructure	14	12	11.6%	20	-29.7%	46	44	5.0%
Facilities Management	0	0	121.2%	5	-90.5%	12	3	346.2%
Others	-2	-15	89.8%	-1	-23.7%	-20	-20	1.1%
Unallocated corporate								
expenses	-4	0	nmf	-8	46.6%	-22	0	nmf
Total	86	55	56.3%	107	-20%	255	466	-45.2%
Margins (%)								
			Difference		Difference			Difference
EBIT	15.6%	14.7%	0.9%	27.6%	-12.0%	18.6%	35.6%	-17.1%
PBT	11.2%	6.8%	4.4%	19.0%	-7.8%	11.2%	28.3%	-17.1%
PAT	5.3%	1.2%	4.1%	11.7%	-6.4%	5.8%	22.8%	-17.1%
Segmental EBIT margi	ns (%)							
			Difference		Difference			Difference
Property	19.9%	8.4%	11.5%	40.4%	-20.5%	31.2%	63.5%	-32.3%
Construction	4.8%	21.2%	-16.5%	1.8%	3.0%	2.1%	13.3%	-11.3%
Infrastructure	48.7%	42.7%	6.0%	67.2%	-18.5%	54.3%	51.2%	3.1%
Facilities Management	2.9%	1.1%	1.8%	24.0%	-21.2%	23.8%	5.1%	18.7%
*FY15 net profit and EPS	figures are	only based	on profit from	n continuir	ng operations			

Fig 2 Results tracking

Source: Company data, Macquarie Research, December 2016

RM 'mil	Macquarie	Actual	% of FY16E	Consensus	Actual	% of FY16E	Macquarie	Consensus I	Difference	
Revenue	1,752	1,376	78.6%	1,745	1,376	78.9%	1,752	1,745	0.4%	
EBIT	277	255	92.3%	274	255	93.3%	277	274	1.1%	
Rep. PAT	119	79	66.8%	110	79	72.3%	119	110	8.2%	
Source: Company data, Bloomberg, Macquarie Research, December 2016										

Macquarie Quant View


The quant model currently holds a reasonably negative view on MRCB. The strongest style exposure is Earnings Momentum, indicating this stock has received earnings upgrades and is well liked by sell side analysts. The weakest style exposure is Valuations, indicating this stock is over-priced in the market relative to its peers.

1482/1899

Global rank in Capital Goods

% of BUY recommendations 50% (4/8)

Number of Price Target downgrades 0 Number of Price Target upgrades 0




Displays where the company's ranked based on the fundamental consensus Price Target and Macquarie's Quantitative Alpha model.

Two rankings: Local market (Malaysia) and Global sector (Capital Goods)


Macquarie Alpha Model ranking

A list of comparable companies and their Macquarie Alpha model score (higher is better).




Factors driving the Alpha Model

For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score.




Macquarie Earnings Sentiment Indicator

The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below.




Drivers of Stock Return

Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple.




What drove this Company in the last 5 years

Which factor score has had the greatest correlation with the company's returns over the last 5 years.



How it looks on the Alpha model

A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market.



Source (all charts): FactSet, Thomson Reuters, and Macquarie Research. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (cpg@macquarie.com)

MRCB (MRC MK, Outperform, Target Price: RM1.85)

MRCB (MRC MK,	Outperfor										
Interim Results		1H/16A	2H/16E	1H/17E	2H/17E	Profit & Loss		2015A	2016E	2017E	2018E
Net Property Income	m	788	964	876	1,070	Net Property Income	m	1,697	1,752	1,946	2,133
Development Income	m	0	0	0	0	Development Income	m	0	0	0	0
Other Revenue	m	0	0	0	0	Other Revenue	m	0	0	0	0
Total Revenue Management Fees	m m	788 0	964 0	876 0	1,070 0	Total Revenue Management Fees	m	1,697 0	1,752 0	1,946 0	2,133 0
Other Expenses	m	-664	-811	-731	-893	Other Expenses	m m	-1,537	-1,475	-1,624	-1,765
EBITDA	m	154	189	179	219	EBITDA	m	242	343	398	456
Dep & Amortisation	m	30	37	34	42	Dep & Amortisation	m	64	67	76	88
EBIT	m	124	152	145	177	EBIT	m	178	277	322	368
Net Interest Income	m	-78	-95	-68	-83	Net Interest Income	m	-146	-172	-150	-139
Associates Exceptionals	m m	13 20	16 24	17 0	20 0	Associates Exceptionals	m m	8 330	30 44	37 0	38 0
Other Pre-Tax Income	m	0	0	0	0	Other Pre-Tax Income	m	0	0	0	0
Pre-Tax Profit	m	80	98	94	115	Pre-Tax Profit	m	370	179	209	267
Tax Expense	m	-19	-24	-23	-28	Tax Expense	m	-6	-43	-50	-64
Net Profit	m	61	75	71	87	Net Profit	m	364	136	158	203
Minority Interests	m	-8	-9	-9	-11	Minority Interests	m	-34	-17	-20	-24
Reported Earnings Adjusted Earnings	m m	53 33	65 41	62 62	76 76	Reported Earnings Adjusted Earnings	m m	330 1	119 74	138 138	179 179
EPS (rep)	sen	3.0	3.1	2.9	3.1	EPS (rep)	sen	17.3	6.1	6.0	7.8
EPS (adj)	sen %	1.9 8,661.2	1.9 8,497.6	2.9 55.1	3.1 59.4	EPS (adj)	sen %	0.0 -95.2	3.8 8,577.5	6.0 57.3	7.8 30.9
EPS Growth yoy (adj)	70	0,001.2	0,497.0	55.1	59.4	EPS Growth (adj) PE (rep)	70 X	-95.2 7.6	21.6	21.9	16.7
						PE (adj)	x	2,994.6	34.5	21.9	16.8
EBITDA Margins	%	19.6	19.6	20.4	20.4	Total DPS	sen	2.5	2.5	2.5	2.5
EBIT Margins	%	15.8	15.8	16.6	16.6	Total Div Yield	%	1.9	1.9	1.9	1.9
Earnings Split Revenue Growth	%	45.0	55.0	45.0	55.0	Basic Shares Outstanding	m	2,350	2,465	2,822	2,720
EBIT Growth	% %	3.3 55.2	3.3 55.2	11.1 16.5	11.1 16.5	Diluted Shares Outstanding	m	1,908	1,956	2,314	2,288
Profit & Loss Ratios		2015A	2016E	2017E	2018E	Cashflow Analysis		2015A	2016E	2017E	2018E
Revenue Growth	%	12.0	3.3	11.1	9.6	EBITDA	m	242	343	398	456
EBITDA Growth	%	-17.6	41.7	15.9	14.6	Tax Paid	m	-81	-43	-50	-64
EBIT Growth	%	-26.2	55.2	16.5	14.2	Chg in Working Capital	m	-194	262	-180	-65
EBITDA Margins	% %	14.3 10.5	19.6 15.8	20.4 16.6	21.4 17.3	Net Interest Paid Other	m	-188 360	-172 0	-150 0	-139 0
EBIT Margins Net Profit Margins	% %	0.0	4.2	7.1	8.4	Operating Cashflow	m m	140	390	1 8	188
Payout Ratio	%	5,715.0	65.9	41.9	32.0	Acquisitions	m	-129	0	0	0
EV/EBITDA	x	22.3	15.1	14.0	12.3	Capex	m	-526	-87	-145	-189
EV/EBIT	x	30.0	18.4	17.0	15.0	Asset Sales	m	218	0	0	0
						Other	m	27	0	0	0
Balance Sheet Ratios	0/	0.0	2.0	F 0	6.0	Investing Cashflow	m	-409	-87 45	-145	-189
ROE ROA	% %	0.0 2.5	3.0 4.0	5.0 4.5	6.2 4.8	Dividend (Ordinary) Equity Raised	m m	-82 0	-45 408	-54 0	-54 0
ROIC	%	3.4	4.1	4.9	5.3	Debt Movements	m	213	-687	306	5
Net Debt/Equity	%	124.2	78.1	82.5	81.0	Other	m	170	0	0	0
Interest Cover	х	1.2	1.6	2.1	2.6	Financing Cashflow	m	300	-323	252	-48
Price/Book Book Value per Share	х	1.4 1.0	1.2 1.1	1.3 1.0	1.2 1.1	Net Chg in Cash/Debt	m	-139	-4	98	-74
						Free Cashflow	m	-385	303	-128	-2
						Balance Sheet		2015A	2016E	2017E	2018E
						Cash	m	522	517	615	542
						Receivables	m	1,095	960	1,066	1,169
						Inventories	m	63	52	63	67
						Investments	m	414	407	400	393
						Fixed Assets	m	337	393	500	640
						Intangibles Other Assets	m m	317 4,342	317 4,247	317 4,489	313 4,614
						Total Assets	m m	7,090	6,894	7,450	7,737
						Payables	m	1,324	1,325	1,471	1,602
						Short Term Debt	m	1,049	677	710	910
						Long Term Debt	m	2,345	2,030	2,303	2,109
						Provisions	m	58	58	58	58
						Other Liabilities Total Liabilities	m m	0 4,777	0 4,091	0 4,543	0 4,680
						Shareholders' Funds	m m	2,260	2,733	2,818	2,944
						Minority Interests	m	53	70	90	113
						Total S/H Equity	m	2,313	2,803	2,908	3,057
						Total Liab & S/H Funds	m	7,090	6,894	7,450	7,737
All figures in MYR unless in Source: Company data, M		earch Decen	nber 2016								
auta, w		, 200011									

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand

Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend vield

Macquarie - Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return

Neutral (Hold) – return within 5% of Russell 3000 index return

Underperform (Sell)– return >5% below Russell 3000 index return

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

Medium – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year.

* Applicable to Asia/Australian/NZ/Canada stocks only

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets

ROA Banks/Insurance = adjusted net profit /average total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 30 September 2016

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	47.26%	55.50%	38.46%	45.47%	59.09%	48.21%	(for US coverage by MCUSA, 8.20% of stocks followed are investment banking clients)
Neutral	38.01%	29.31%	42.86%	48.77%	37.88%	36.79%	(for US coverage by MCUSA, 8.25% of stocks followed are investment banking clients)
Underperform	14.73%	15.19%	18.68%	5.76%	3.03%	15.00%	(for US coverage by MCUSA, 8.00% of stocks followed are investment banking clients)



(all figures in MYR currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, November 2016

12-month target price methodology

MRC MK: RM1.85 based on a Sum of Parts methodology

Company-specific disclosures:

MRC MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

DateStock Code (BBG code)RecommendationTarget Price07-Nov-2016MRC MKOutperformRM1.85

Target price risk disclosures:

MRČ MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited and Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient

you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated.

Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered brokerdealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index_jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS030020010000000&serviceId=SDIS03000000000. South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc., accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York,

© Macquarie Group

Asia Research

Head of Equity Research

Peter Redhead (Global - Head)	(852) 3922 4836
Jake Lynch (Asia – Head)	(852) 3922 3583
David Gibson (Japan – Head)	(813) 3512 7880
Conrad Werner (ASEAN – Head)	(65) 6601 0182

Automobiles/Auto Parts

Janet Lewis (China)	(852) 3922 5417
Zhixuan Lin (China)	(8621) 2412 9006
Leo Lin (China)	(852) 3922 1098
Takuo Katayama (Japan)	(813) 3512 7856
James Hong (Korea)	(822) 3705 8661
Amit Mishra (India)	(9122) 6720 4084

Financials

Scott Russell (Asia)	(852) 3922 3567
Dexter Hsu (China, Taiwan)	(8862) 2734 7530
Elaine Zhou (Hong Kong)	(852) 3922 3278
Keisuke Moriyama (Japan)	(813) 3512 7476
Chan Hwang (Korea)	(822) 3705 8643
Suresh Ganapathy (India)	(9122) 6720 4078
Gilbert Lopez (Philippines)	(632) 857 0892
Passakorn Linmaneechote (Thailand)	(662) 694 7728

Conglomerates

David Ng (China, Hong Kong)	(852) 3922 1291
Conrad Werner (Singapore)	(65) 6601 0182
Gilbert Lopez (Philippines)	(632) 857 0892

Consumer and Gaming

Linda Huang (Asia, China, Hong Kong)	(852) 3922 4068
Zibo Chen (China, Hong Kong)	(852) 3922 1130
Terence Chang (China, Hong Kong)	(852) 3922 3581
Satsuki Kawasaki (Japan)	(813) 3512 7870
Mike Allen (Japan)	(813) 3512 7859
Kwang Cho (Korea)	(822) 3705 4953
KJ Lee (Korea)	(822) 3705 9935
Stella Li (Taiwan)	(8862) 2734 7514
Amit Sinha (India)	(9122) 6720 4085
Fransisca Widjaja	(65) 6601 0847
(Indonesia, Singapore)	
Karisa Magpayo (Philippines)	(632) 857 0899
Chalinee Congmuang (Thailand)	(662) 694 7993

Emerging Leaders

Jake Lynch (Asia)	(852) 3922 3583
Aditya Suresh (Asia)	(852) 3922 1265
Timothy Lam (China, Hong Kong)	(852) 3922 1086
Mike Allen (Japan)	(813) 3512 7859
Kwang Cho (Korea)	(822) 3705 4953
Corinne Jian (Taiwan)	(8862) 2734 7522
Marcus Yang (Taiwan)	(8862) 2734 7532
Conrad Werner (ASEAN)	(65) 6601 0182

Industrials

Janet Lewis (Asia)	(852) 3922 5417
Patrick Dai (China)	(8621) 2412 9082
Leo Lin (China)	(852) 3922 1098
Kunio Sakaida (Japan)	(813) 3512 7873
James Hong (Korea)	(822) 3705 8661
Inderjeetsingh Bhatia (India)	(9122) 6720 4087

Internet, Media and Software

(852) 3922 3378
(813) 3512 7880
(852) 3922 3716
(813) 3512 7875
(822) 3705 8659
(9122) 6720 4088

Oil, Gas and Petrochemicals

Polina Diyachkina (Asia, Japan)	(813) 3512 7886
Aditya Suresh (Asia, China)	(852) 3922 1265
Anna Park (Korea)	(822) 3705 8669
Duke Suttikulpanich (ASEAN)	(65) 6601 0148
Isaac Chow (Malaysia)	(603) 2059 8982

Pharmaceuticals and Healthcare

Abhishek Singhal (India)

Wei Li (China, Hong Kong)

Property	
Tuck Yin Soong (Asia, Singapore	e) (65) 6601 0838
David Ng (China, Hong Kong)	(852) 3922 1291
Raymond Liu (China, Hong Kong	g) (852) 3922 3629
Wilson Ho (China)	(852) 3922 3248
William Montgomery (Japan)	(813) 3512 7864
Corinne Jian (Taiwan)	(8862) 2734 7522
Abhishek Bhandari (India)	(9122) 6720 4088
Aiman Mohamad (Malaysia)	(603) 2059 8986
Kervin Sisayan (Philippines)	(632) 857 0893
Patti Tomaitrichitr (Thailand)	(662) 694 7727

Resources / Metals and Mining

Polina Diyachkina (Asia, Japan)	(813) 3512 7886
Coria Chow (China)	(852) 3922 1181
Anna Park (Korea)	(822) 3705 8669

Technology

Damian Thong (Asia, Japan)	(813) 3512 7877
George Chang (Japan)	(813) 3512 7854
Daniel Kim (Korea)	(822) 3705 8641
Allen Chang (Greater China)	(852) 3922 1136
Jeffrey Ohlweiler (Greater China)	(8862) 2734 7512
Patrick Liao (Greater China)	(8862) 2734 7515
Louis Cheng (Greater China)	(8862) 2734 7526
Kaylin Tsai (Greater China)	(8862) 2734 7523

Telecoms

Nathan Ramler (Asia, Japan)	(813) 3512 7875
Danny Chu (Greater China)	(852) 3922 4762
Soyun Shin (Korea)	(822) 3705 8659
Prem Jearajasingam (ASEAN)	(603) 2059 8989
Kervin Sisayan (Philippines)	(632) 857 0893

Transport & Infrastructure

Janet Lewis (Asia)	(852) 3922 5417
Corinne Jian (Taiwan)	(8862) 2734 7522
Azita Nazrene (ASEAN)	(603) 2059 8980

Utilities & Renewables

Alan Hon (Hong Kong)	(852) 3922 3589
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Karisa Magpayo (Philippines)	(632) 857 0899

Commodities

Colin Hamilton (Global)	(44 20) 3037 4061
Ian Roper	(65) 6601 0698
Jim Lennon	(44 20) 3037 4271
Lynn Zhao	(8621) 2412 9035
Matthew Turner	(44 20) 3037 4340

Economics

(9122) 6720 4086

(852) 3922 5494

Peter Eadon-Clarke (Global)	(813) 3512 7850
arry Hu (China, Hong Kong)	(852) 3922 3778
Tanvee Gupta Jain (India)	(9122) 6720 4355

Quantitative / CPG

Gurvinder Brar (Global)	(44 20) 3037 4036
Woei Chan (Asia)	(852) 3922 1421
Danny Deng (Asia)	(852) 3922 4646
Per Gullberg (Asia)	(852) 3922 1478

Strategy/Country

Viktor Shvets (Asia, Global)	(852) 3922 3883
Chetan Seth (Asia)	(852) 3922 4769
David Ng (China, Hong Kong)	(852) 3922 1291
Erwin Sanft (China, Hong Kong)	(852) 3922 1516
Peter Eadon-Clarke (Japan)	(813) 3512 7850
Chan Hwang (Korea)	(822) 3705 8643
Jeffrey Ohlweiler (Taiwan)	(8862) 2734 7513
Inderjeetsingh Bhatia (India)	(9122) 6720 408
Jayden Vantarakis (Indonesia)	(6221) 2598 8310
Anand Pathmakanthan (Malaysia)	(603) 2059 8833
Gilbert Lopez (Philippines)	(632) 857 0892
Conrad Werner (Singapore)	(65) 6601 0182
Alastair Macdonald (Thailand)	(662) 694 7753

Find our research at

Macquarie:	www.macquarie.com.au/research
Thomson:	www.thomson.com/financial
Reuters:	www.knowledge.reuters.com
Bloomberg:	MAC GO
Factset:	http://www.factset.com/home.aspx
CapitalIQ	www.capitalig.com
Email macroscoarch	@macquaria com for accoss

Asia Sales

Regional Heads of Sales

(1 212) 231 6121 (1 617) 598 2508 Miki Edelman (Global) Jeff Evans (Boston) Jeffrey Shiu (China, Hong Kong) (852) 3922 2061 Sandeep Bhatia (India) Thomas Renz (Geneva) (9122) 6720 4101 (41 22) 818 7712 (6221) 2598 8486 Riaz Hyder (Indonesia) Nick Cant (Japan) (65) 6601 0210 John Jay Lee (Korea) (822) 3705 9988 Nik Hadi (Malaysia) (603) 2059 8888 Eric Roles (New York) (1 212) 231 2559 Gino C Rojas (Philippines) (632) 857 0861

Regional Heads of Sales cont'd

Paul Colaco (San Francisco)	(1 415) 762 5003
Amelia Mehta (Singapore)	(65) 6601 0211
Angus Kent (Thailand)	(662) 694 7601
Ben Musgrave (UK/Europe)	(44 20) 3037 4882
Christina Lee (UK/Europe)	(44 20) 3037 4873
Sales Trading	

(852) 3922 2002 Adam Zaki (Asia) (6221) 515 1555 Stanley Dunda (Índonesia)

Sales Trading cont'd

Suhaida Samsudin (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Chris Reale (New York)	(1 212) 231 2555
Marc Rosa (New York)	(1 212) 231 2555
Justin Morrison (Singapore)	(65) 6601 0288
Daniel Clarke (Taiwan)	(8862) 2734 7580
Brendan Rake (Thailand)	(662) 694 7707
Mike Keen (UK/Europe)	(44 20) 3037 4905